Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 2/20 | 0.38 |
| ▸ | CHUK | O15111 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | CCNK | O75909 | 8/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 8/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.32 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3416746 | 0.87 | PRKCI (0.40) | PRKCIIKBKBCHUKROCK1DAO | |
| SCHEMBL3417614 | 0.86 | PRKCI (0.37) | PRKCIIKBKBCHUKROCK1DAO | |
| SCHEMBL2239319 | 0.85 | CHUK (0.51) | PRKCIIKBKBCHUKROCK1DAO | |
| SCHEMBL3418231 | 0.85 | PRKCI (0.40) | PRKCIIKBKBCHUKROCK1DAO | |
| SCHEMBL13013845 | 0.84 | CCNK (0.39) | PRKCIIKBKBCHUKROCK1DAO | |
| SCHEMBL13507021 | 0.83 | IKBKB (0.34) | PRKCIIKBKBCHUKROCK1DAO | |
| Trifluoroacetic Acid SCHEMBL3418240 | 0.80 | IKBKB (0.35) | PRKCIIKBKBCHUKROCK1DAO | |
| SCHEMBL32671221 | 0.80 | PRKCI (0.44) | PRKCIIKBKBCHUKDAOCCNK | |
| SCHEMBL3415216 | 0.79 | SMN1; SMN2 (0.45) | CDK12 | |
| SCHEMBL3418244 | 0.77 | IKBKB (0.34) | PRKCIIKBKBCHUKROCK1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035917-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20080176891-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-07-24 | — | — | US | disclosed |
| US-20080146606-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176891-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | PRKCI 24/4885IKBKB 4/4885CHUK 8/4885 |
| US-20100035917-A1 | PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS | PLK2, PDXK, MAP4K2 | PRKCI 373/4885IKBKB 428/4885CHUK 300/4885 |
| US-20080146606-A1 | NOVEL COMPOUNDS | NFKBIA, IKBKG, IKBKE | PRKCI 24/4885IKBKB 4/4885CHUK 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.